Laura Dixon, APRN
Gerontology · Lakeland, FLNPI 1992104152
Payments from drug & device makers
Across 736 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Biohaven Pharmaceuticals, Inc.$982
- AbbVie$826
- Pfizer$801
- plus $5K from 31 others
What the payments were for
- Consulting fees$8007%
- Food & beverage$10,98893%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 123 | $1,895 |
| Lilly USA, LLC | 105 | $1,402 |
| AstraZeneca | 52 | $1,124 |
| Biohaven Pharmaceuticals, Inc. | 21 | $982 |
| AbbVie | 67 | $826 |
| Pfizer | 67 | $801 |
| Novartis | 40 | $609 |
| Amgen(2 entities) | 45 | $526 |
| Boehringer Ingelheim | 40 | $524 |
| Dexcom, Inc. | 21 | $403 |
| Biohaven Pharmaceutical Holding Company Ltd. | 31 | $379 |
| GSK | 17 | $320 |
| Bayer | 14 | $263 |
| Johnson & Johnson | 15 | $220 |
| Exact Sciences | 8 | $178 |
| Daiichi Sankyo Inc. | 7 | $153 |
| Esperion Therapeutics, Inc. | 7 | $114 |
| Merck | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Vifor Pharma, Inc. | 1 | $96 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Abbott | 5 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $86 |
| Tolmar, Inc. | 5 | $78 |
| Amarin Pharma, Inc. | 4 | $75 |
| Currax Pharmaceuticals LLC | 4 | $52 |
| Astellas Pharma US Inc | 3 | $50 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Antares Pharma, Inc. | 3 | $44 |
| Corcept Therapeutics | 2 | $37 |
| Vivus LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- AIRSUPRA$352
- FARXIGA$352
- Wegovy$239
How this compares
$11,802 in reported general payments places this provider in the 95th percentile of 714 gerontology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $122,935 |
| MounjaroTirzepatide | 72 | $106,816 |
| EliquisApixaban | 103 | $90,486 |
| RybelsusSemaglutide | 39 | $41,557 |
| GemtesaVibegron | 56 | $35,109 |
| XareltoRivaroxaban | 24 | $33,574 |
| MyrbetriqMirabegron | 38 | $30,868 |
| WegovySemaglutide | 17 | $22,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $20,109 |
| FarxigaDapagliflozin Propanediol | 13 | $16,545 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,484 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,645 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,804 |
| Atorvastatin Calcium | 228 | $2,567 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,895 | $186,849143 claims |
| Lilly USA, LLCMounjaro | $1,402 | $106,81672 claims |
| PfizerEliquis | $801 | $90,486103 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $48 | $35,10956 claims |
| Johnson & JohnsonXarelto | $220 | $33,57424 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $320 | $31,23843 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $30,86838 claims |
| AstraZenecaFarxiga, Symbicort | $1,124 | $19,07924 claims |
| AbbVieSynthroid | $826 | $1,95227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 gerontology providers in Florida.
Other gerontology in Lakeland
- Georgette FarmerLakeland$11K
- Noureen DhananiThe Villages$276K
- Flavius NascimentoCoral Springs$226K
- Michelle HartogWinter Park$90K
- Alejandra Rosales-CohenOrange City$88K
- Jennifer PacilettiAtlantis$66K
- Tatiana ClarkBradenton$34K
- Brandi LigonWinter Park$27K
- Boni MayOrlando$22K
- Dennis VerducciMiami$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.